Neoantigen quality predicts immunoediting in survivors of pancreatic cancer is a research paper published in Nature (2022). On theSindex it has a DataRank of 4.3. It has been cited 204 times, with 180 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.798
From this paper's citation signal
Citation Network Contribution
3.5
From 152 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 180 citers.
NCI NIH HHS
Grant: P30 CA008748
NIH HHS
Grant: P30 CA08748
NCI NIH HHS
Grant: U01 CA224175
National Institutes of Health
Grant: 1U01CA224175-01
Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapy
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals